Search Results
10
Everything
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
March 24, 2025 08:00 ET
|
CG Oncology Inc.
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
March 12, 2025 08:00 ET
|
CG Oncology Inc.
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP
March 06, 2025 08:30 ET
|
Biodexa Pharmaceuticals PLC
March 6, 2025 Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP Biodexa is finalizing plans to initiate an international...
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
February 26, 2025 08:00 ET
|
CG Oncology Inc.
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 16, 2024 16:05 ET
|
CG Oncology Inc.
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CG Oncology Announces Pricing of Public Offering
December 12, 2024 20:19 ET
|
CG Oncology Inc.
CG Oncology Announces Pricing of Public Offering
CG Oncology Announces Proposed Public Offering
December 11, 2024 06:17 ET
|
CG Oncology Inc.
CG Oncology Announces Proposed Public Offering
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
December 05, 2024 07:00 ET
|
CG Oncology Inc.
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
December 02, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
Comprehensive Epidemiology Forecast Reveals Significant Insights into Prader-Willi Syndrome Through 2034
December 02, 2024 04:42 ET
|
Research and Markets
Dublin, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The "Non-Muscle Invasive Bladder Cancer (NMIBC) - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.Demographics and...